Molecular Partners AG - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
MOLN Nasdaq 2830 www.molecularpartners.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Molecular Partners AG

Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1 - May 30th, 2026 6:00 am
Molecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit - May 26th, 2026 2:00 pm
Eckert & Ziegler SE (XTER:EUZ) Q1 2026 Earnings Call Highlights: Strong Medical Division ... - May 13th, 2026 7:03 pm
Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317 - May 12th, 2026 2:00 pm
Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences - May 3rd, 2026 11:00 pm
Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling - May 1st, 2026 5:00 am
Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712 - Apr 19th, 2026 10:00 am
Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting - Apr 14th, 2026 2:00 pm
3 European Penny Stocks With Market Caps Under €600M - Apr 6th, 2026 5:05 am
Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors - Mar 23rd, 2026 7:00 am
Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins’ Amenability to Multiple Isotopes - Mar 19th, 2026 12:00 am
Molecular Partners to Hold Three Poster Presentations at AACR 2026 - Mar 17th, 2026 2:30 pm
Molecular Partners Reports Highlights and Financial Results for Full Year 2025 - Mar 12th, 2026 2:00 pm
Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results - Feb 25th, 2026 11:00 pm
Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics - Feb 25th, 2026 11:00 pm
Molecular Partners Highlights Favorable MP0712 DLL3 Radiotherapeutic Imaging, U.S. Phase I/II Ready - Feb 2nd, 2026 1:30 pm
Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026 - Feb 1st, 2026 11:00 pm
Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference - Jan 11th, 2026 1:00 pm
Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference - Dec 17th, 2025 11:00 pm
Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics - Dec 11th, 2025 5:00 am